Highlights
- Izalontamab brengitecan (iza-bren), a bispecific antibody-drug conjugate targeting EGFR and HER3 with a topoisomerase I inhibitor payload, showed significant progression-free survival (PFS) improvement over standard chemotherapy in heavily pretreated HR+/HER2- breast cancer.
- The PANKU-Breast01 trial conducted exclusively in China offers important regional clinical evidence in a population with limited treatment options after endocrine therapy, CDK4/6 inhibitors, and chemotherapy.
- Hematological toxicities were the predominant adverse events with iza-bren, underscoring the need for supportive care strategies focusing on platelet management.
- Overall survival data remain immature; future global studies may elucidate long-term benefits and inform earlier line use in HER2-negative breast cancer.
Background
Specialty calculators
For clinical reference; use professional judgment.
